摘要
前列腺癌为常见男性实体器官恶性肿瘤,具有较高发病率和死亡率。转移性去势抵抗性前列腺癌(CRPC)是多数前列腺癌患者病情发展的转归,其临床治疗效果及预后较差,中位总生存期不足2年。部分CRPC患者因前期雄激素剥夺治疗或化学治疗发生耐药抵抗,因此制定有效的治疗方案尤为重要。近年临床用于治疗CRPC的新型内分泌药物主要有醋酸阿比特龙、恩扎卢胺及阿帕他胺等,而靶向治疗和免疫治疗等新疗法也在研发中。本文对CRPC治疗现状及进展进行了总结。
Prostate cancer(PCa) is the most common solid neoplasm in men, with high morbidity and mortality. Most PCa progress to castration-resistant prostate cancer(CRPC) with poor clinical outcomes and prognosis. The median overall survival(OS) can be less than 2 years in patients with mCRPC. Strategies to optimize the order of therapeutic regimens are important for CRPC patients, due to drug resistance caused by previous androgen deprivation therapy(ADT) or chemotherapy. This review will provide an overview on the present and future therapies for CRPC, including targeted and immunotherapy, and recent drugs such as abiraterone acetate, enzalutamide and apalutamide, being utilized in clinic.
作者
贾泽鹏
陈泽宇
高旭(审校)
JIA Zepeng;CHEN Zeyu;GAO Xu(Department of Urology,Changhai Hospital of Naval Medical University,Shanghai,200433,China)
出处
《临床泌尿外科杂志》
2020年第4期312-316,320,共6页
Journal of Clinical Urology
关键词
去势抵抗性前列腺癌
雄激素剥夺治疗
阿比特龙
恩扎卢胺
靶向治疗
castration-resistant prostate cancer
androgen deprivation therapy
abiraterone
enzalutamide
targeted therapy
